| 9.34 -0.05 (-0.53%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.53 | 1-year : | 13.47 |
| Resists | First : | 9.88 | Second : | 11.53 |
| Pivot price | 8.34  |
|||
| Supports | First : | 7.86 | Second : | 6.61 |
| MAs | MA(5) : | 9.38 |
MA(20) : | 8.14 |
| MA(100) : | 7.87 |
MA(250) : | 7.53 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 83.7 |
D(3) : | 85.9 |
| RSI | RSI(14): 70.5 |
|||
| 52-week | High : | 9.88 | Low : | 4.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MGTX ] has closed below upper band by 21.7%. Bollinger Bands are 169.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.52 - 9.58 | 9.58 - 9.62 |
| Low: | 9.13 - 9.21 | 9.21 - 9.27 |
| Close: | 9.24 - 9.35 | 9.35 - 9.44 |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Tue, 07 Apr 2026
Insider Sell Alert: Stuart Naylor Sells Shares of MeiraGTx Holdings PLC - GuruFocus
Tue, 07 Apr 2026
MeiraGTx (MGTX) CDO Stuart Naylor sells 27,661 shares via 10b5-1 plan - Stock Titan
Tue, 07 Apr 2026
Naylor, MeiraGTx chief dev. officer, sells $258,906 in shares - Investing.com
Sat, 04 Apr 2026
MGTX Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 01 Apr 2026
MeiraGTx Holdings plc Ordinary Shares MGTX ) Stock Price Today & Analysis - Gotrade
Wed, 01 Apr 2026
What Does The Future Hold For MeiraGTx Holdings plc (NASDAQ:MGTX)? These Analysts Have Been Cutting Their Estimates - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 81 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 20 (%) |
| Held by Institutions | 65.8 (%) |
| Shares Short | 5,300 (K) |
| Shares Short P.Month | 5,190 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | -140.4 % |
| Operating Margin | 35.1 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -368.2 % |
| Qtrly Rev. Growth | 252.3 % |
| Gross Profit (p.s.) | 0.94 |
| Sales Per Share | 1 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6.58 |
| PEG Ratio | 0 |
| Price to Book value | -133.43 |
| Price to Sales | 9.3 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|